Catalyst Wire Dossier Catalyst Wire Dossier

Rinvoq (upadacitinib)

Upadacitinib · AbbVie
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Rinvoq (upadacitinib), covering 2025-02-10 to 2025-02-10. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis [Phase 1]

See pricing